Table 5.
Univariate analysis for CNS involvement in patients with PTCLs
| RR | 95% CI | P value | |
| Sex | |||
| Male | |||
| Female | 1.773 | 0.706–4.455 | 0.223 |
| Age (years) | |||
| ≤50 | |||
| >50 | 0.969 | 0.385–2.438 | 0.947 |
| Serum LDH | |||
| ≤Upper normal limit | |||
| >Upper normal limit | 5.904 | 1.334–26.123 | 0.019 |
| B symptoms | |||
| Absent | |||
| Present | 1.528 | 0.586–3.988 | 0.386 |
| Ann Arbor stage | |||
| I/II | |||
| III/IV | 1.609 | 0.452–5.731 | 0.463 |
| Extranodal involvement | |||
| 0–1 | |||
| 2 or more | 1.724 | 0.686–4.329 | 0.247 |
| Visceral organ involvement | |||
| Absent | |||
| Present | 2.358 | 0.934–5.956 | 0.069 |
| PS | |||
| 0–1 | |||
| 2–4 | 2.018 | 0.796–5.118 | 0.139 |
| Paranasal sinus involvement | |||
| Absent | |||
| Present | 3.137 | 1.105–8.908 | 0.032 |
| Bone marrow involvement | |||
| Absent | |||
| Present | 0.667 | 0.246–1.805 | 0.425 |
| IPI | |||
| I/II | |||
| III/IV | 0.666 | 0.255–1.737 | 0.406 |
| PIT | |||
| III/IV | |||
| I/II | 0.489 | 0.188–1.275 | 0.143 |
CNS, central nervous system; PTCL, peripheral T-cell lymphoma; RR, relative risk; CI, confidence interval; LDH, lactate dehydrogenase; PS, performance status; IPI, international prognostic index; PIT, prognostic index for PTCL-NOS.